GLYC Glycomimetics Inc

Price (delayed)

$2.43

Market cap

$125.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.22

Enterprise value

-$4.68M

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has declined by 24% year-on-year and by 8% since the previous quarter
GLYC's quick ratio is down by 16% YoY but it is up by 11% QoQ
Glycomimetics's revenue has plunged by 78% from the previous quarter and by 75% YoY
The gross profit has dropped by 78% since the previous quarter and by 75% year-on-year

Key stats

What are the main financial stats of GLYC
Market
Shares outstanding
51.54M
Market cap
$125.24M
Enterprise value
-$4.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
55.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.11
Earnings
Revenue
$2.22M
EBIT
-$57.64M
EBITDA
-$56.67M
Free cash flow
-$49.93M
Per share
EPS
-$1.22
Free cash flow per share
-$0.98
Book value per share
$2.43
Revenue per share
$0.04
TBVPS
$2.72
Balance sheet
Total assets
$138.02M
Total liabilities
$12.9M
Debt
$2.6M
Equity
$125.12M
Working capital
$122.87M
Liquidity
Debt to equity
0.02
Current ratio
12.33
Quick ratio
12.22
Net debt/EBITDA
2.29
Margins
EBITDA margin
-2,554.6%
Gross margin
100%
Net margin
-2,598.2%
Operating margin
-2,600.2%
Efficiency
Return on assets
-39.1%
Return on equity
-42.9%
Return on invested capital
N/A
Return on capital employed
-45.3%
Return on sales
-2,598.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLYC stock price

How has the Glycomimetics stock price performed over time
Intraday
0.83%
1 week
12.5%
1 month
-6.9%
1 year
-21.86%
YTD
-35.37%
QTD
-19.27%

Financial performance

How have Glycomimetics's revenue and profit performed over time
Revenue
$2.22M
Gross profit
$2.22M
Operating income
-$57.68M
Net income
-$57.64M
Gross margin
100%
Net margin
-2,598.2%
Glycomimetics's revenue has plunged by 78% from the previous quarter and by 75% YoY
The gross profit has dropped by 78% since the previous quarter and by 75% year-on-year
Glycomimetics's net income has decreased by 13% QoQ and by 12% YoY
Glycomimetics's operating income has decreased by 12% from the previous quarter and by 6% YoY

Growth

What is Glycomimetics's growth rate over time

Valuation

What is Glycomimetics stock price valuation
P/E
N/A
P/B
1
P/S
55.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.11
The company's EPS fell by 9% QoQ
GLYC's price to book (P/B) is 60% lower than its 5-year quarterly average of 2.5 and 17% lower than its last 4 quarters average of 1.2
Glycomimetics's equity has decreased by 16% YoY and by 2.4% from the previous quarter
GLYC's P/S is 87% above its last 4 quarters average of 29.7
Glycomimetics's revenue has plunged by 78% from the previous quarter and by 75% YoY

Efficiency

How efficient is Glycomimetics business performance
The ROE has contracted by 35% YoY and by 18% from the previous quarter
Glycomimetics's return on assets has decreased by 33% YoY and by 17% QoQ

Dividends

What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLYC.

Financial health

How did Glycomimetics financials performed over time
Glycomimetics's current ratio has decreased by 17% YoY but it has increased by 11% QoQ
GLYC's quick ratio is down by 16% YoY but it is up by 11% QoQ
The debt is 98% smaller than the equity
The debt has declined by 24% year-on-year and by 8% since the previous quarter
Glycomimetics's equity has decreased by 16% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.